Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
The completion of liquidation of an overseas consolidated subsidiary(recording of extraordinary profit)and revision of consolidated earnings forecast
TAIKO PHARMA, Net Income Forecast for the Fiscal Year Revised Upward by 50%
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2025 (FY2025)
TAIKO PHARMA, First Half Ordinary Profit Decreases by 96%, Apr-Jun Ordinary Profit Decreases by 97%
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2025 (Under Japanese GAAP)
TAIKO PHARMA, Jan-Mar (1Q) Ordinary Profit Decreases by 95%
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2025 (Under Japanese GAAP)
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2025 (FY2025)
[Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (FY2024)
TAIKO PHARMA, 71% Decrease in Ordinary Profit for The Current Fiscal Year
Consolidated Financial Results for the Fiscal Year Ended December 31,2024(Under Japanese GAAP)
TAIKO PHARMACEUTICAL CO., LTD., January-September (Third Quarter Cumulative) Ordinary Profit Turns to Profit, Exceeds Full-Year Plan
Summary of Financial Results for the third quarter 2024